Respiratory syncytial virus (RSV) is a leading cause of severe respiratory disease in children, the elderly and immunocompromised individuals. There is currently no licensed RSV vaccine. High titers of RSV-specific antibodies can provide protection against severe RSV-induced disease; however, even the highest antibody titers fail to protect some individuals against RSV reinfection and disease. Thus, the correlates of protective immunity against RSV remain unclear. Memory CD8 T cells can provide protective immunity against a wide range of acute viral infections, including respiratory viruses such as influenza virus and the severe acute respiratory syndrome (SARS) human coronavirus. In most virus infections, memory CD8 T cells mediate viral clearance without causing substantial damage to the infected host. Because it is clear that antibodies alone are not sufficient to provide complete protection against RSV infection, we hypothesized that induction of a strong pre-existing RSV-specific memory CD8 T cell response in the absence of RSV-specific memory CD4 T cells and antibodies would provide protective immunity against an RSV infection. In order to test our hypothesis we modified an accelerated prime/boost approach to generate robust pre-existing memory CD8 T cell populations specific to the immunodominant M282-90 epitope. Our preliminary data indicate that RSV- specific memory CD8 T cells can significantly inhibit viral replication, but unexpectedly do so at the cost of causing fatal immunopathology upon RSV challenge. Importantly, the immunopathology was not an inherent property of the T cells, as RSV-specific memory CD8 T cells were capable of mediating protection without immunopathology against a lethal challenge with a recombinant influenza virus expressing the RSV-derived M282-90 epitope. Our data reveal that the design of a strictly T cell-based RSV vaccine could have severe consequences. Thus, important knowledge gaps exist regarding how RSV-specific memory CD8 T cells function to control RSV infection and the mechanisms that result in the development of immunopathology. The goal of this proposal is to address these critical knowledge gaps and provide mechanistic insight into if memory CD8 T cells can be manipulated to confer optimal protective immunity against RSV infection. We will achieve these goals by pursuing the following three specific aims:
Aim 1. Determine the mechanism of memory CD8 T cell-mediated immunopathology following RSV infection.
Aim 2. Investigate the characteristics of memory CD8 T cells that enhance immunity and limit immunopathology after RSV challenge.
Aim 3. Define the optimal correlates of protection against RSV infection. The knowledge gained from these studies will provide vital information regarding the correlates of protective immunity to RSV, information that will greatly impact the design and evaluation of future RSV vaccine candidates. !
Respiratory syncytial virus (RSV) is the leading cause of lower respiratory tract infection in children and a previous experimental RSV vaccine led to enhanced morbidity and mortality in vaccinated children following natural RSV infection. Thus, RSV has a substantial impact on public health in the United States. Thus, the proposed research is relevant to the part of the NIH?s mission that pertains to developing new vaccines and therapeutic interventions aimed at reducing disease burden caused by RSV.
| Van Braeckel-Budimir, Natalija; Varga, Steven M; Badovinac, Vladimir P et al. (2018) Repeated Antigen Exposure Extends the Durability of Influenza-Specific Lung-Resident Memory CD8+ T Cells and Heterosubtypic Immunity. Cell Rep 24:3374-3382.e3 |
| Schmidt, Megan E; Knudson, Cory J; Hartwig, Stacey M et al. (2018) Memory CD8 T cells mediate severe immunopathology following respiratory syncytial virus infection. PLoS Pathog 14:e1006810 |
| Schmidt, Megan E; Varga, Steven M (2018) The CD8 T Cell Response to Respiratory Virus Infections. Front Immunol 9:678 |
